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Background: Physician prescribing is the most frequent medical intervention with a highest impact on healthcare
costs and outcomes. Therefore improving and promoting rational drug use is a great interest. We aimed to assess
the effectiveness and cost-effectiveness of two forms of conducting prescribing audit and feedback interventions
and a printed educational material intervention in improving physician prescribing.
Method/design: A four-arm randomized trial with economic evaluation will be conducted in Tehran. Three
interventions (routine feedback, revised feedback, and printed educational material) and a no intervention control
arm will be compared. Physicians working in outpatient practices are randomly allocated to one of the four arms
using stratified randomized sampling. The interventions are developed based on a review of literature, physician
interviews, current experiences in Iran and with theoretical insights from the Theory of Planned Behavior. Effects of
the interventions on improving antibiotics and corticosteroids prescribing will be assessed in regression analyses.
Cost data will be assessed from a health care provider’s perspective and incremental cost-effectiveness ratios will be
calculated.
Discussion: This study will determine the effectiveness and cost-effectiveness of three interventions and allow us
to determine the most effective interventions in improving prescribing pattern. If the interventions are cost-
effective, they will likely be applied nationwide.
Trial registration: Iranian Registry of Clinical Trials Registration Number: IRCT201106086740N1Pharmaceutical
Sciences Research Center of TUMS Ethics Committee Registration Number: 90-02-27-07
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Over the past decades, new generations of antibiotics,
analgesics, corticosteroids and other medicines have
been introduced to the pharmaceuticals market. At
the same time, health care systems are confronted
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distribution, and reproduction in any mediumcare in the face of increasing costs and limited finan-
cial resources.
Due to the rising pharmaceutical expenditures in the
world, governments are struggling to keep costs under
control [1-3]. There are valid concerns about the ration-
ality of use of medicines, mostly as a result of inappro-
priate physician prescribing. Physicians’ prescribing is
the most common medical intervention with a high im-
pact on health care costs [4]. Improving and promoting
rational use of medicines contributes to a more efficient
use of meager health care resources, as well as ensuring
better population health outcomes.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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quire complex multilayered interventions [5]. Such inter-
ventions may include using audit and feedbacks,
dissemination of printed educational materials, educa-
tional outreach visits, reminders, and opinion leaders
among others [6,7]. Implementing the multilayered
intervention is more costly and resource intensive.
Hence, it is important to identify easy to implement an
effective intervention to improve physicians’ prescribing.
Several studies have been conducted to develop inter-
ventions and strategies to improve prescribing [8-13] but
most of them have been carried out in high-income
countries, sometimes with conflicting results [14]. Only
limited high quality studies exist from low and middle-
income countries.
According to a Cochrane Review, audit and feedback
is defined as a summary of health care performance
over a specified period of time with or without recom-
mendations for a clinical action [15]. Evidence from
118 randomized controlled trials indicated that audit
and feedback resulted in a modest improvement in
care [15]. Grimshaw and colleagues [16] undertook a
comprehensive review of the effects of using different
strategies for implementing guidelines. They found that
audit and feedback alone or combined with educa-
tional meetings and materials result in a modest im-
provement in the implementation of guidelines in
comparison to no intervention group. Furthermore the
studies on assessing the effectiveness of printed educa-
tional materials indicated only a small impact on prac-
tice, but there was no reliable assessment of the cost
effectiveness of such programs. As the small benefits
from dissemination of printed educational materials
are achieved at relatively low costs, they may still be
worthwhile interventions [17,18].
In Iran for many years, the problems of irrational
drug use have been investigated by academic members
of several universities [19-24]. In 1996, the National
Committee of Rational Use of Drug (NCRUD) was
established and a formal process of assessing physician
prescribing started in the country. To make this pos-
sible, different data sources were developed that
included a central data warehouse as well as access to
insurance organization prescription datasets. Also dif-
ferent interventions including audit and feedbacks, dis-
semination of printed educational materials, public
education and workshops and conferences were
employed. Although these national plans were not sub-
jected to formal evaluations, descriptive assessments
suggest that they may have resulted in improving pre-
scribing behavior, including a descending trend in the
mean medicine items per prescription as an important
indicator for rational drug use [25,26]. So far, no sys-
tematic and scientific evaluation has been conductedto determine the effectiveness and cost effectiveness of
audit and feedback interventions in Iran. This trial is
designed to test three different interventions for im-
proving rational drug use indicators of general physi-
cians, pediatricians and infectious disease specialists.
The main objectives of the study are:
1) Does the routinely conducted prescribing audit and
feedback intervention influence general physicians,
pediatricians and infectious disease specialists
prescribing behavior in comparison to printed
educational materials and no intervention?
2) Does a revised audit and feedback intervention
improve prescribing behavior compared to the
routinely conducted prescribing audit and feedback,
printed educational materials and no intervention?
At the same time, we evaluated cost-effectiveness of
the interventions compared to the control groups.
Methods
Study design
The study design is a four- armed randomized con-
trolled trial with economic evaluation. It includes three
different intervention arms and one control arm: rou-
tinely conducted audit and feedback, revised audit and
feedback, printed educational materials (pamphlets), and
a no intervention control group (see Trial Flow in
Figure 1).
Population and setting
The target population included general physicians,
pediatricians and infectious disease specialists who have
an outpatient practice in Tehran, and have a current
contract with at least one of the two main social health
insurance organizations.
Details of the interventions
Routinely conducted audit and feedback involves a
three-page summary of prescriptions indicators based on
the analysis of insured prescriptions. The summary
reports the prescribing indicators for each physician in
comparison with their peer groups in the same area in a
given time period (annual and quarterly). The first page
is cover letter signed by the Secretary of the RUD com-
mittee in the region, consisting of general points about
the common problems especially in the area which they
practice. The second page includes physician’s profile
such as name, specialty, medical council number, office
address, the evaluation period and the insurance
organization that have provided prescription data. Then,
the prescription amount of main indicators will be listed
in comparative tables that include the following:
1. Average medicine items per prescription
Data at baseline, one month and 3 months after the intervention will be 
collected and analysed
General physicians, pediatricians and infectious 
disease specialists in Tehran
Eligibility
Having an outpatient practice in Tehran, and have a current contract with at least 
one of the two main social health insurance organizations
Randomize 1:1:1:1 ; stratified by















Figure 1 Trial flow proposed physicians enrollment and randomization procedures.
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3. Proportion of prescriptions including one medicine
item (%)
4. Proportion of prescriptions including four or more
medicine items (%)
5. Maximum medicine items in a prescription
6. Proportion of injectable medicine items per all
prescribed items (%)
7. Proportion of prescriptions that includes at least one
injectable medicine item (%)
Consequently, the prescription indicators for important
drug groups such as antibiotics, corticosteroids and NSAIDs
will be reported. These groups will be chosen based upon
common prescribing problems in any given area. More-
over, the list of 10 most-prescribed drugs and 10 first most
expensive drugs are reported in separate tables. Finally, 10
important drug interactions with high severity and inten-
sity in the physician’s prescriptions are reported [27].
The revised audit and feedback has been developed for
this trial based on current drug use problems in Iran. We
developed our intervention based on four inputs: the
current audit and feedback, a literature review, interviews
with physicians, and the theoretical justifications acquired
from the Theory of Planned Behavior (TPB).
We conducted a literature review to obtain feedback’
samples from other countries [28] and identifyingcurrent and important drug prescribing problems in our
country [25,26]. Face-to-face interviews were conducted
with16 physicians.
The TPB [29] is a social cognition theory to provide
a theoretical basis for explaining volitional behavior.
The theory has important merits in explaining and
understanding physician behavior, including prescribing
[30-33]. The TPB suggests that individuals’ intention
to perform behaviors is determined by their attitudes,
perceived social or peer pressures (subjective norms)
and perceived behavioral control [Figure 2].
The revised feedback form consisted of three pages.
The form uses traffic light colors for reporting the pre-
scribing indicators by physicians. Based on the findings
from interviews, the revised feedback form was designed
to look less crowded than the routinely conducted feed-
back and to ensure physicians’ attention was attracted
towards important messages in the feedback. The indica-
tors were also selected more objectively. The first page
expresses the purpose of providing feedback and inter-
preting the colors used in the report and the importance
of improving the situation of irrational prescribing
signed by secretary of the committee. If dexamethasone
and ceftriaxone injectable forms and an oral form of
cefixime are at the beginning of the list of 10 most pre-
scribed drugs, notice will be given. The revised feedback




















Figure 2 Theory of Planned Behavior [6].
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2. Average price per prescription (IR Rials)
3. Proportion of prescriptions including four or more
medicine items (%)
4. Proportion of prescriptions that includes at least one
injectable medicine item (%)
5. Proportion of prescriptions that includes at least one
antibiotic medicine item (%)
6. Proportion of prescriptions that includes at least one
corticosteroid medicine item (%)
In the second page, table of the most prescribed anti-
biotics in the country as prescribed by each physician
are reported. Then, a graph reports all antibiotics pre-
scribed by a physician and his/her peer group according
to differentiate seasons. At the bottom of the second
page, two important practice points related to prescrib-
ing antibiotics are presented.
Table of prescription amount of most prescribed sys-
temic corticosteroids in the country as prescribed by the
physician are presented on the third page. Then, a graph
reports all injectable forms of medicines prescribed by
the physician and compares it with his/her peer group.
At the bottom of the third page, two important practice
points related to prescription of injectable forms of med-
icines and corticosteroids are presented.
Printed educational material (pamphlet)
The educational material was also developed using lit-
erature review, interviews with physicians, with theoret-
ical attentions based on the TPB. Most physicians
participating in the interviews emphasized on theusefulness of a concise pamphlet with a practical train-
ing content. Hence, a 4-page A5 size pamphlet was
designed. The pamphlet provides practical tips on pre-
scribing antibiotics, corticosteroids and injectable dosage
forms and the current status of utilization of these medi-
cines in the country. It also documents examples of ser-
ious adverse effects reported from inappropriate usage
of ceftriaxone injections and serious complications after
dexamethasone injections.
Study setting and participants
The study is conducted in Tehran. All general physi-
cians, pediatricians and infectious disease specialists who
have an outpatient practice in Tehran, issue a minimum
of 100 prescriptions per month, and have a current con-
tract with at least one of the two main social health in-
surance organizations are eligible for inclusion in the
study.
Sample size calculation and allocation to the intervention
arms
Considering that about 14% of outpatient prescriptions
in Tehran contain dexamethasone injections and expect-
ing that the intervention may reduce such prescriptions
by 10%, we aimed to recruit 200 participants in each
study arm (i.e. a total 800 participants).
As the interventions will be delivered to all the physi-
cians allocated to the study arms (effectiveness trial) and
that we used routinely collected data to assess the
effects, the prospect of loss to follow was low.
To allocate the participants to the study arms, we first
prepare a list of all eligible physicians working in Tehran
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into the three physician groups (i.e. general physicians,
pediatricians, infectious disease specialists). Within each
group we will randomly select the required number of
physicians, proportional to the size of each group. Using
a random number generator, the participants will be
allocated to the study arms, and use the physician group
and the contracted insurance organization as the strati-
fying factors. As a result we will have, in each study arm,
175 general physicians, 24 pediatricians, and four infec-
tious disease specialists (totaling 203 physicians in each
arm). Random numbers will be generated by a member
of the team who is not involved in the delivery of the
interventions.
Outcome measures
The main outcome measures for assessing the effective-
ness of the interventions, the percentage of change in
the proportion of dexamethasone injectable form, oral
form of cefixime and amoxicillin which prescribed by
general physicians, pediatricians and infectious disease
specialists will be considered.
Costs are assessed from a health care provider perspec-
tive. We include all identifiable costs related to the imple-
mentation of the interventions. Our analysis therefore
focuses on the incremental costs of developing and imple-
menting audit and feedback and printed educational ma-
terial interventions. Recurring and non-recurring costs are
considered. Nonrecurring costs include revising the com-
puter software and designing the new format of the feed-
back, and the pamphlet. Recurring costs include printing
materials, travel costs, postage costs and other administra-
tive tasks.
Study procedures and data collection
Data at baseline, one month and 3 months after the
intervention will be collected.
Statistical and cost-effectiveness analyses
Demographic and baseline analyses will be conducted to
ensure random allocation procedure has been effective
in producing comparable study arms. Chi-square, t-test,
repeated measure ANOVA and logistic regression ana-
lyses will be the primary modes of analyzing the results.
As the primary outcomes, we will assess the effects of
the study arms on the proportion of prescriptions con-
taining each of the target prescribed medicines. We will
also assess the effects of the interventions on the mean
cost per prescription, and the mean number of items
prescribed per prescription. Appropriate interaction ana-
lyses will be conducted to assess the interactions be-
tween the selected variables and the interventions. A
fixed-effect two-level analysis approach will be followedin which prescriptions will be used as the first level and
the physicians as the second level of data.
Cost data will be assessed using the actual costs in-
curred in the study, from a health care provider view
point. Incremental cost-effectiveness ratios will be calcu-
lated and sensitivity analyses will be also conducted to
assess the effects of changes in important variables in
the cost-effectiveness of the interventions.
Intention-to-treat analyses will be carried out with
physicians as the primary analysis approach. We will also
conduct a per protocol analysis as a sensitivity analysis.
Ethical considerations
These data have been extracted from the Health Insur-
ance Organization claims database and are provided
confidentially for each physician for personal review.
This study was approved by the Ethics Committee of
Pharmaceutical Sciences Research Center of TUMS and
has been registered with the Center for International
Registration of Clinical Trial.
Discussion
A thorough evaluation of the intervention for improving
and promoting rational drug use may bring important
benefits, whereas inappropriate prescribing may lead to
undesirable consequences. We see this trial as a neces-
sary prerequisite for the development and implementa-
tion of a cost-effective intervention that will improve
and promote rational drug use in Iran.
This study will determine the effectiveness of the three
interventions, and allow us to determine what kind of
intervention will be the most effective in improving pre-
scribing pattern. This work will be the first to assess the
effectiveness and cost-effectiveness of the routinely con-
ducted audit and feedback that has been widely used in
the country.
The risk of contamination between the study arms is a
potential limitation of the study. However as the study
sample is selected from a large number of physicians
working in Tehran, the risk of contamination should be
small. Additional potential limitation of the study may
arise due to concurrent interventions that might happen
by the responsible authorities within the Ministry of
Health and Medical Education, as well as the universities
in charge of health care in Tehran. We will follow such
activities throughout the study, and will assess their po-
tential impacts on the study findings, if they occur.
We believe that the current proposal may have other
benefits. We expect that it will lead to the development of
focused interventions that could greatly promote rational
drug use. Changing physician’s behavior is challenging and
involves attention to the views and concerns of practicing
physicians. We attended to the physicians’ views while
developing our interventions. In addition, this trial shall
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used as a novel format of interventions for promoting ra-
tional drug use. We hope that, if our interventions are
cost-effective, they shall be widely applied nationwide. The
interventions may also be of use in middle income coun-
tries with appropriate infrastructures.
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